Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Sell
39
BAX Quote, Financials, Valuation and Earnings
Last price:
$30.97
Seasonality move
:
2.3%
Day range:
$30.12 - $31.20
52-week range:
$28.34 - $44.01
Dividend yield:
3.36%
P/E ratio:
154.75x
P/S ratio:
0.91x
P/B ratio:
2.01x
Volume:
6.9M
Avg. volume:
4.8M
1-year change:
-20.74%
Market cap:
$15.8B
Revenue:
$14.8B
EPS (TTM):
$0.20
Analysts' Opinion
-
Consensus RatingBaxter International has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 12 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $40.08, Baxter International has an estimated upside of 29.51% from its current price of $30.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 3.07% downside risk from its current price of $30.95.
Fair Value
-
According to the consensus of 16 analysts, Baxter International has 29.51% upside to fair value with a price target of $40.08 per share.
BAX vs. S&P 500
-
Over the past 5 trading days, Baxter International has overperformed the S&P 500 by 2.65% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Baxter International does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Baxter International has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Baxter International reported revenues of $2.7B.
Earnings Growth
-
Baxter International earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Baxter International reported earnings per share of $0.27.
Enterprise value:
27.4B
EV / Invested capital:
--
Price / LTM sales:
0.91x
EV / EBIT:
119.08x
EV / Revenue:
1.58x
PEG ratio (5yr expected):
--
EV / Free cash flow:
70.05x
Price / Operating cash flow:
40.33x
Enterprise value / EBITDA:
17.96x
Gross Profit (TTM):
$5.8B
Return On Assets:
0.39%
Net Income Margin (TTM):
0.63%
Return On Equity:
1.33%
Return On Invested Capital:
0.49%
Operating Margin:
5.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $13.8B | $13.6B | $17.3B | $2.6B | $2.7B | |
| Gross Profit | $4.8B | $4.8B | $5.8B | $1.1B | $1B | |
| Operating Income | $369M | $623M | $555M | $179M | $150M | |
| EBITDA | -$1.2B | $1.6B | $1.5B | $292M | $299M | |
| Diluted EPS | -$4.72 | $5.10 | $0.20 | $4.93 | $0.27 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9B | $8.2B | $7.8B | $12B | $8.9B | |
| Total Assets | $20.1B | $19.8B | $28B | $30.7B | $26.7B | |
| Current Liabilities | $3.4B | $3.4B | $3.7B | $6.2B | $6.2B | |
| Total Liabilities | $11.5B | $11B | $22.4B | $22.5B | $18.7B | |
| Total Equity | $8.6B | $8.8B | $5.6B | $8.2B | $7.9B | |
| Total Debt | $6.5B | $6B | $16.4B | $16.5B | $12.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.5B | $1.6B | $1.1B | $365M | $253M | |
| Cash From Investing | -$10.9B | $3.2B | -$651M | $3.8B | -$164M | |
| Cash From Financing | $8B | -$673M | -$4.2B | -$62M | -$146M | |
| Free Cash Flow | $844M | $1.1B | $391M | $352M | $229M | |
BAX
Sector
Market Cap
$15.8B
$45.4M
Price % of 52-Week High
70.33%
46.67%
Dividend Yield
3.36%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-20.74%
-33.9%
Beta (5-Year)
0.596
0.747
Dividend yield:
3.36%
Annualized payout:
$1.16
Payout ratio:
546.3%
Growth streak:
7 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$30.07
200-day SMA
Sell
Level
$35.45
Bollinger Bands (100)
Sell
Level
31.11 - 38.09
Chaikin Money Flow
Buy
Level
923.8M
20-day SMA
Buy
Level
$29.54
Relative Strength Index (RSI14)
Buy
Level
55.80
ADX Line
Buy
Level
21.24
Williams %R
Sell
Level
-8.726
50-day SMA
Sell
Level
$31.60
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
477.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0953)
Sell
CA Score
(Annual)
Level (-1.3348)
Buy
Beneish M-Score
(Annual)
Level (-2.7075)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.9113)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter has signed an agreement to sell its kidney care tools by early 2025.
Stock Forecast FAQ
In the current month, BAX has received 3 Buy ratings 12 Hold ratings, and 1 Sell ratings. The BAX average analyst price target in the past 3 months is $40.08.
-
Where Will Baxter International Stock Be In 1 Year?
According to analysts, the consensus estimate is that Baxter International share price will rise to $40.08 per share over the next 12 months.
-
What Do Analysts Say About Baxter International?
Analysts are divided on their view about Baxter International share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Baxter International is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Baxter International's Price Target?
The price target for Baxter International over the next 1-year time period is forecast to be $40.08 according to 16 Wall Street analysts, 3 of them rate the stock a Buy, 1 rates the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is BAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Baxter International is a Hold. 12 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BAX?
You can purchase shares of Baxter International via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Baxter International shares.
-
What Is The Baxter International Share Price Today?
Baxter International was last trading at $30.97 per share. This represents the most recent stock quote for Baxter International. Yesterday, Baxter International closed at $30.95 per share.
-
How To Buy Baxter International Stock Online?
In order to purchase Baxter International stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Why Is Stanley Druckenmiller Buying Citigroup?
As recently as 2020, few analysts could have predicted that…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
NUTX alert for Jan 17
Nutex Health [NUTX] is up 2.83% over the past day.
Buy
53
QMCO alert for Jan 17
Quantum [QMCO] is down 15.61% over the past day.
Sell
34
NGVT alert for Jan 17
Ingevity [NGVT] is up 1.31% over the past day.
